Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06832878

Postoperative Oral Tranexamic Acid in Patients Undergoing Primary Total Joint Arthroplasty

The purpose of this study is to evaluate the impact of an extended oral Tranexamic Acid regimen on patient reported outcome scores, time to independent ambulation, postoperative range of motion, swelling, change in hemoglobin levels, 90-day complications, readmission and reoperation.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Arthroplasty

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged > 18 years (All women of childbearing potential undergo pregnancy testing prior to THA as per our institutional protocol)
  • Written informed consent
  • Patients undergoing primary THA diagnosis of end-stage osteoarthritis
  • Patients receiving spinal anesthesia
  • Patients being discharged on postoperative day 1

Exclusion criteria

  • Patients with a TXA allergy
  • Patients undergoing revision procedures
  • Patients undergoing primary THA for a diagnosis other than end-stage osteoarthritis
  • Patients receiving general anesthesia
  • Patients being discharged on the same day of surgery
  • Cancer patients
  • Patients with a history of prior VTE event
  • Patients on preoperative anticoagulants other than ASA
  • Pregnant patients (All women of child bearing potential undergo pregnancy testing prior to THA as per our institutional protocol)
  • Female patients who are on hormonal contraception
  • Patients with history of retinal vein or artery occlusion

Treatment and study plan

oral tranexamic acid

Drug

Subjects will receive a 1.95 g dose of oral TXA at the following timepoints: (1) following ambulation, (2) postoperative day 1, (3) postoperative day 2, and (4) postoperative day 3

Primary outcomes

  1. Visual Analog Score

    Time frame: Baseline, 3 days postoperative, 2 weeks, 6 weeks, 12 weeks

    The VAS is a 11-item questionnaire assessing pain. Using a scale of 0 = no pain to 10 = worst pain. Total scores range from 0 - 110, lower scores indicating lower pain and higher scores indicating greater pain.

  2. Hip Disability and Osteoarthritis Outcome Score (HOOS) for Joint Replacement (JR)

    Time frame: Baseline, 3 days postoperative, 2 weeks, 6 weeks, 12 weeks

    The Hip Disability and Osteoarthritis Outcome Score (HOOS) for Joint Replacement (JR) is a questionnaire designed to measure outcomes for patients with hip replacements. Results are scored 0-11. 0 = total hip disability, 100 = perfect hip health.

Secondary outcomes

  1. Hemoglobin

    Time frame: Baseline, prior to discharge, day 3 postoperatively

    Hemoglobin is a protein within red blood cells. As glucose enters the bloodstream, it binds to hemoglobin, or glycates. The more glucose that enters the bloodstream, the higher the amount of glycated hemoglobin. An A1C level below 5.7 percent is considered normal. Reported as percentage of glycated hemoglobin

  2. Harris Hip Score (HHS)

    Time frame: Baseline, 3 days postoperative, 2 weeks, 6 weeks, 12 weeks

    The Harris Hip Score (HHS) is a tool used to assess hip function and the results of hip treatments, such as hip replacements. It's a 100-point scale that measures four areas: pain, function, deformity, and range of motion. A higher score indicates less dysfunction and better outcomes. A score of less than 70 is considered poor, 70-80 is fair, 80-90 is good, and 90-100 is excellent.

  3. Short Form Health Survey (SF-12)

    Time frame: Baseline, 3 days postoperative, 2 weeks, 6 weeks, 12 weeks

    The 12-Item Short Form Health Survey (SF-12) is a questionnaire which consists of 12 questions covering physical and mental health domains. Scores above 50 indicate a better-than-average health-related quality of life, while scores below 50 suggest below-average health.

  4. Time to Independent Ambulation

    Time frame: 12 weeks

    Duration of time post-operation until the subject can walk without any support or assistance, reported in days

  5. Oxford Hip Score

    Time frame: Baseline, 3 days postoperative, 2 weeks, 6 weeks, 12 weeks

    The Oxford Hip Score (OHS) is a standard patient-reported outcome (PRO) measure, or PROM, developed to assess function and pain in patients undergoing total hip replacement (THR) surgery, particularly in the context of clinical trials. The OHS has also been used for the assessment of patient outcomes, including physical therapy, and use of joint supplements (disease specific and general health measure are two other outcome measures).

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Feb 18, 2025
Registry last updated
Feb 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.